Dr. Savona is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 The Vanderbilt Clini
Nashville, TN 37232Phone+1 615-322-3000Fax+1 615-936-0605
Summary
- Michael Savona is Chief of Hematology, Cellular Therapy and Stem Cell Transplantation, and Professor of Medicine and Cancer Biology at Vanderbilt University Medial Center. He graduated from Davidson College, served in the USAF, received his medical degree from Wake Forest University School of Medicine in 2002. He is board certified in hematology specializes in caring for patients with chronic myeloid disorders (e.g. myeloproliferative neoplasms, bone marrow failure syndromes, aplastic anemia, myelodysplasia, and acute myeloid leukemia). He has more than 100 publications and over 500 citings.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2005 - 2008
University of California Davis HealthResidency, Internal Medicine, 2002 - 2005
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2002
Certifications & Licensure
TN State Medical License 2011 - 2026
AL State Medical License 2020 - 2020
MI State Medical License 2005 - 2012
TX State Medical License 2008 - 2011
CA State Medical License 2004 - 2006- American Board of Internal Medicine Hematology
Clinical Trials
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
- TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea Start of enrollment: 2015 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.Tamanna Haque, Aditi Shastri, Pinkal Desai, Zhuoer Xie, Danielle Hammond
British Journal of Haematology. 2024-12-09 - Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic ...Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, John M Bennett, Rafael Bejar
Modern Pathology. 2024-12-01 - Methylation sequencing enhances interpretation of clonal hematopoiesis dynamics.Alyssa C Parker, Joseph Van Amburg, J Brett Heimlich, Yash Pershad, Nicole Angelina Mickels
Blood. 2024-11-20
Abstracts/Posters
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Oral Azacitidine and Cedazuridine Approximate Azacitidine Efficacy in a Murine ModelMichael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of th...Michael R. Savona, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Translating Pathophysiological Advances Into Innovative Treatments for Myelodysplastic Syndromes and Related Myeloid Neoplasms60th American Society of Hematology Annual Meeting - 11/30/2018
Authored Content
- In Oral Maintenance Therapy in AML, Do All Roads Lead to the Epigenome?November 2020
Press Mentions
Potential Treatment Eyed for Abnormal Blood Cell DisorderNovember 25th, 2024- Form 8-K Forma Therapeutics Holdi for: May 26May 26th, 2022
- CAR-T Therapy Ushering in a New Era of Precision Medicine for Patients with Chronic Lymphocytic LeukemiaMarch 11th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
